Invirsa Completes $7.7M Series B Financing
COLUMBUS, Ohio--(BUSINESS WIRE)--Invirsa Inc., a privately held, clinical-stage pharmaceutical company focused on developing an innovative topically administered eyedrop formulation INV-102 for ocular conditions associated with DNA damage, announced the closing of a $7.7 million Series B financing completed in April...
United States John Rice Robert Shalwitz Department Of Health Invirsa Inc Biomedical Advanced Research
Source: pharmiweb.com